Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

“Staying informed is more important than ever given the changing market dynamics of healthcare.” I have been fortunate to attend the National A...

View Blog Post
Blog Post

A paper in the Perspectives section of the New England Journal of Medicine (Feb 22 issue, 2018) discussed the problem of benzodiazepine abuse, examining both the ...

View Blog Post
Blog Post

At the time of this writing, a record 52.2 inches of rain had fallen on the Big Island o...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up